|
Vol. 12, Issue 10, 1591-1598, October 2002
RESOURCES
An AscI Boundary Library for the Studies of Genetic and Epigenetic Alterations in CpG Islands
Zunyan
Dai,1,2
Dieter
Weichenhan,4
Yue-Zhong
Wu,1
Julia L
Hall,1
Laura J.
Rush,1,3
Laura T.
Smith,1
Aparna
Raval,1
Li
Yu,1
Daniela
Kroll,5
Joerg
Muehlisch,5
Michael C.
Frühwald,5
Pieter
de Jong,6
Joe
Catanese,6
Ramana V.
Davuluri,1
Dominic J.
Smiraglia,1 and
Christoph
Plass1,7
1 Division of Human Cancer Genetics, Department of
Molecular Virology, Immunology and Medical Genetics,
2 Department of Pathology, 3 Department of Veterinary
Biosciences, and the Comprehensive Cancer Center, The Ohio State
University, Columbus, Ohio 43210, USA; 4 Medizinische
Universität zu Lübeck, Medizinische Klinik II, Ratzeburger
Allee 160 23538 Lübeck, Germany; 5 Klinik und Poliklinik
für Kinderheilkunde, Pädiatrische
Hämatologie/Onkologie, Universitätsklinikum Münster,
48149 Münster, Germany; 6 Children's Hospital, Oakland
Research Institute, Oakland,
California 94609, USA
Knudson's two-hit hypothesis postulates that genetic alterations in
both alleles are required for the inactivation of tumor-suppressor genes. Genetic alterations include small or large deletions and mutations. Over the past years, it has become clear that epigenetic alterations such as DNA methylation are additional mechanisms for gene
silencing. Restriction Landmark Genomic Scanning (RLGS) is a
two-dimensional gel electrophoresis that assesses the methylation status of thousands of CpG islands. RLGS has been applied successfully to scan cancer genomes for aberrant DNA methylation patterns. So far,
the majority of this work was done using NotI as the
restriction landmark site. Here, we describe the development of RLGS
using AscI as the restriction landmark site for genome-wide
scans of cancer genomes. The availability of AscI as a
restriction landmark for RLGS allows for scanning almost twice as many
CpG islands in the human genome compared with using NotI only.
We describe the development of an AscI-EcoRV
boundary library that supports the cloning of novel methylated genes.
Feasibility of this system is shown in three tumor types,
medulloblastomas, lung cancers, and head and neck cancers. We report
the cloning of 178 AscI RLGS fragments via two methods by use
of this library.
[Supplemental material is available online
at http://www.genome.org.]
7
Corresponding author.
12:1591-1598 ©2002 by Cold Spring Harbor Laboratory Press ISSN 1088-9051/02 $5.00

CiteULike Connotea Del.icio.us Digg Reddit Technorati What's this?
This article has been cited by other articles:

|
 |

|
 |
 
R. M. Brena and J. F. Costello
Genome-epigenome interactions in cancer
Hum. Mol. Genet.,
April 15, 2007;
16(R1):
R96 - R105.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
L. J. Rush, A. Raval, P. Funchain, A. J. Johnson, L. Smith, D. M. Lucas, M. Bembea, T.-H. Liu, N. A. Heerema, L. Rassenti, et al.
Epigenetic Profiling in Chronic Lymphocytic Leukemia Reveals Novel Methylation Targets
Cancer Res.,
April 1, 2004;
64(7):
2424 - 2433.
[Abstract]
[Full Text]
[PDF]
|
 |
|

|
 |

|
 |
 
Z. Dai, W.-G. Zhu, C. D. Morrison, R. M. Brena, D. J. Smiraglia, A. Raval, Y.-Z. Wu, L. J. Rush, P. Ross, J. R. Molina, et al.
A comprehensive search for DNA amplification in lung cancer identifies inhibitors of apoptosis cIAP1 and cIAP2 as candidate oncogenes
Hum. Mol. Genet.,
April 1, 2003;
12(7):
791 - 801.
[Abstract]
[Full Text]
[PDF]
|
 |
|
|
|